In Vitro Efficacy Testing Services for Lymphoma

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Lymphoma. Our services offer comprehensive efficacy testing to evaluate candidate compounds targeting key molecular pathways implicated in Lymphoma pathogenesis, including immune checkpoint modulation, apoptosis regulation, and cell signaling networks. We focus on critical proteins such as PD-1/PD-L1, Bcl-2 family members, and intracellular signaling mediators. Our assays enable detailed analysis of processes such as immune escape, dysregulated apoptosis, and abnormal cell proliferation characteristic of Lymphoma.

Our portfolio comprises a diverse range of cell-based, biochemical, and biophysical in vitro assays designed to profile compound efficacy and mechanism of action in Lymphoma models. These methods enable the assessment of target engagement, pathway modulation, and cellular response, supporting drug discovery and lead optimization. Each assay is tailored to provide actionable data for advancing therapeutic candidates.

Arrestin protease recruitment assay: Measures GPCR activation by detecting arrestin-protease recruitment, useful for evaluating signaling modulation in lymphoma-relevant pathways.

Bioluminescent assay: Utilizes luminescent reporters to quantify cellular responses such as viability or pathway activation, providing sensitive detection of drug effects.

CHO-K1 Chinese hamster ovary cells transfected with human CD274/aAPC: Employs engineered CHO-K1 cells expressing human PD-L1 to study immune checkpoint interactions and drug modulation.

Chemiluminescent assay: Detects molecular interactions or activity changes using chemiluminescent substrates, offering high sensitivity for low-abundance targets.

Competitive binding assay (qPCR): Quantifies binding affinity of test compounds to target molecules via competition, combined with qPCR detection for specificity.

Displacement of fluorescent Bid-BH3 peptide: Assesses compound binding to anti-apoptotic Bcl-2 proteins by measuring displacement of a labeled Bid-BH3 peptide, relevant for apoptosis studies.

Displacement of fluorescent Bim-BH3 peptide: Similar to Bid-BH3 assays, monitors displacement of Bim-BH3 peptide to evaluate interactions with apoptosis regulators.

ELISA assay: Quantifies protein or antibody concentrations using enzyme-linked immunosorbent detection, ideal for cytokine release and biomarker analysis.

Flow cytometry assay: Analyzes cell populations and surface marker expression, enabling assessment of cell phenotype, apoptosis, and immune modulation.

Fluorescence resonance energy transfer (FRET) assay: Measures proximity-based molecular interactions using energy transfer between fluorophores, useful for signaling or binding studies.

Fluorescent assay: General category for assays that utilize fluorescent readouts to measure enzyme activity, binding events, or cell viability.

Fluorescent polarization assay: Detects binding interactions by monitoring changes in polarization of fluorescent ligands, suitable for affinity and displacement studies.

Fluorescent-activated cell sorting (FACS) assay: Enables quantitative sorting and analysis of cell subpopulations based on fluorescent markers, critical for functional immune assays.

Homogeneous Time Resolved Fluorescence (HTRF) assay: Combines fluorescence detection and time-resolved measurement to assess biomolecular interactions in a high-throughput format.

Jurkat human T-cell leukemia cells transfected with PD1/NFAT/luciferase: Uses engineered Jurkat cells to study T-cell activation and PD-1 pathway modulation via luciferase reporter activity.

Jurkat human T-cell leukemia cells transfected with human PD1/NFAT/luciferase: Similar to above, with humanized PD-1 for precise evaluation of human immune checkpoint inhibitors.

Surface plasmon resonance assay: Real-time, label-free measurement of biomolecular binding kinetics, providing quantitative analysis of compound-target interactions.

We measure a comprehensive set of pharmacological parameters that quantify compound potency, binding affinity, and inhibitory activity. These readouts are essential for comparing candidate efficacy and guiding structure-activity relationship (SAR) optimization. Accurate parameter determination supports informed decision-making in preclinical drug development.

EC-50: The concentration of a compound that produces 50% of its maximal effect; critical for assessing drug potency.

IC-50: The concentration required to inhibit a biological process or target by 50%; commonly used to compare inhibitor effectiveness.

Kd: The equilibrium dissociation constant reflecting binding affinity between a drug and its target; lower Kd indicates stronger binding.

Ki: The inhibition constant measuring how effectively a compound inhibits a specific enzyme or receptor; important for characterizing competitive inhibitors.

MIC: Minimum inhibitory concentration, representing the lowest concentration of a compound that prevents visible growth of target cells; relevant for cytotoxicity and antimicrobial evaluation.

Recommended In Vitro Efficacy Tests

Bcl2 Apoptosis Regulator

The Bcl2 Apoptosis Regulator is pivotal in lymphoma by inhibiting programmed cell death, promoting tumor survival. Testing Bcl2 activity is crucial for identifying and developing effective lymphoma therapeutics. Our service utilizes competitive binding (qPCR), FRET, chemiluminescent, displacement of fluorescent Bim-BH3 peptide, and fluorescence polarization assays to assess Bcl2 interactions. We deliver key parameters—IC-50, Ki, and MIC—providing essential data for drug candidate evaluation and optimization.

Bcl2 Like 2

Bcl2 Like 2 (BCL2L2) is an anti-apoptotic protein implicated in lymphoma cell survival and drug resistance. Testing BCL2L2 expression and function is vital for developing targeted lymphoma therapies and predicting treatment response. Key methods include qPCR, Western blotting, and immunohistochemistry. Main parameters measured are BCL2L2 mRNA/protein levels, apoptosis rates, and response to drug treatments, enabling precise evaluation of drug efficacy and mechanism of action.

Bcl2 Related Protein A1

Bcl2 Related Protein A1 is an anti-apoptotic protein implicated in lymphoma cell survival and drug resistance. Testing A1’s function is crucial for identifying effective therapeutics targeting apoptosis pathways. Our service measures A1 inhibition via displacement of a fluorescent Bid-BH3 peptide, providing accurate Ki values. This enables precise assessment of compound potency, supporting the development of targeted lymphoma therapies.

C-X-C Motif Chemokine Receptor 4

C-X-C Motif Chemokine Receptor 4 (CXCR4) plays a pivotal role in lymphoma progression and metastasis. Accurate CXCR4 testing is crucial for developing targeted therapies. Our service utilizes advanced methods including flow cytometry, FRET, fluorescent, arrestin protease recruitment, and HTRF assays. Key parameters measured—IC-50, Ki, and MIC—enable precise evaluation of drug efficacy and receptor inhibition, accelerating lymphoma drug development with robust, reproducible data.

Mdm2 Proto-Oncogene

The Mdm2 proto-oncogene negatively regulates p53, promoting lymphoma cell survival and proliferation. Testing its activity is crucial for evaluating drug efficacy in lymphoma therapy development. Utilizing bioluminescent and chemiluminescent assays, this service quantifies Mdm2 activity and determines drug potency, primarily through EC-50 values, enabling precise assessment of candidate compounds targeting the Mdm2-p53 pathway.

Mechanistic Target Of Rapamycin Kinase

The Mechanistic Target Of Rapamycin (mTOR) kinase plays a pivotal role in lymphoma progression by regulating cell growth and survival. mTOR kinase testing is essential for evaluating potential therapeutics targeting this pathway. Using chemiluminescent assays, our service accurately measures key parameters such as IC-50 (half-maximal inhibitory concentration) and MIC (minimum inhibitory concentration), providing critical data to advance lymphoma drug development.

Nuclear Receptor Subfamily 3 Group C Member 1

Nuclear Receptor Subfamily 3 Group C Member 1 (NR3C1), encoding the glucocorticoid receptor, regulates apoptosis and proliferation in lymphoma cells. NR3C1 testing is crucial for predicting glucocorticoid therapy response and resistance during lymphoma drug development. Key methods include qPCR, immunohistochemistry, and Western blotting, assessing NR3C1 gene expression, protein levels, and receptor functionality. Main parameters measured are NR3C1 mRNA/protein expression and receptor activity.

Programmed Cell Death 1

The Programmed Cell Death 1 (PD-1) testing service supports lymphoma drug development by assessing PD-1’s role in immune evasion. This testing is crucial for evaluating novel immunotherapies. Key methods include flow cytometry, ELISA, HTRF, FACS, surface plasmon resonance, and cellular assays using transfected Jurkat and CHO-K1 cells. Main parameters measured are EC-50, IC-50, Kd, and MIC, providing essential data on drug efficacy and binding affinity.

T Cell Immunoreceptor With Ig And Itim Domains

T Cell Immunoreceptor With Ig And ITIM Domains (TIGIT) plays a crucial immunosuppressive role in lymphoma, affecting tumor immune evasion. Testing TIGIT expression and function is vital for optimizing immunotherapy strategies. Our service employs flow cytometry, surface plasmon resonance, ELISA, and FACS assays to assess TIGIT activity. We provide key parameters such as IC-50 and Kd, supporting robust evaluation of drug candidates targeting TIGIT in lymphoma drug development.